
    
      The purpose of this study is to compare the effectivness and the safety of sarilumab in
      patients with glucocorticoid-dependent sarcoidosis. To demonstrate that sarilumab treatment
      will be effective for inducing and maintaining glucocorticoid-free remission in male or
      female patients with biopsy proven active, glucocorticoid-dependent sarcoidosis affecting the
      lungs, lymph nodes, liver, kidneys, spleen, bone, soft tissues, skin, and/or eyes.
    
  